Perigon Wealth Management
RPRX icon

Perigon Wealth Management’s Royalty Pharma RPRX Stock Holding History

Perigon Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$384K Buy
6,577
+581
+10% +$34.3K 0.01% 1030
2026
Q2 		$336K Buy
5,996
+206
+4% +$10.7K 0.01% 1053
2026
Q1 		$278K Buy
+5,790
New +$254K 0.01% 1049
2024
Q4 		– Sell
-21,562
Closed -$610K – 1087
2024
Q3 		$610K Buy
+21,562
New +$597K 0.02% 558

Other funds holding RPRX

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Hosking Partners
Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return
Kepler Cheuvreux
Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return
Kirr Marbach & Co
Kirr Marbach & Co Columbus, Indiana $530M AUM 14.37% 1-Year Est. Return
Triasima Portfolio Management
Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

Perigon Wealth Management's RPRX Position: Q3 2026 in Review

Perigon Wealth Management increased its Royalty Pharma (RPRX) stake by 9.7% in Q3 2026, buying an estimated $34.3K and bringing the position to 6,577 shares worth $384K. The position accounts for 0.01% of the portfolio, ranked #1030.

Perigon Wealth Management first reported a position in RPRX in Q3 2024 and has held it in 4 quarters since. The position peaked at $610K in Q3 2024. 120 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Perigon Wealth Management held 6,577 shares of Royalty Pharma worth $384K as of Q3 2026.
  • Perigon Wealth Management bought 581 Royalty Pharma shares in Q3 2026, an estimated $34.3K.
  • Royalty Pharma made up 0.01% of Perigon Wealth Management's portfolio in Q3 2026, its #1030 holding.
  • Perigon Wealth Management first reported a position in Royalty Pharma in Q3 2024 and has held it in 4 quarters since.
  • Perigon Wealth Management's Royalty Pharma position peaked at $610K in Q3 2024.
  • 120 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Perigon Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.